Stroke Thrombolysis

Although 8 yr have passed since the Food and Drug Administration (FDA) released tissue plasminogen activator (t-PA) for use in the United States to treat patients with acute ischemic stroke, thrombolysis is still very controversial. Clearly, thrombolysis is a step forward but there remain problems with its use, and with the guidelines and policies that direct its application.